Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceuticals North America has made Actoplus met XR, an extended-release version of the combination medication Actoplus met (pioglitazone HCl and metformin Hcl), available, in the US pharmacies. Actoplus met XR is used for the treatment of type 2 diabetes as an add-on to diet and exercise.
Subscribe to our email newsletter
Takeda Pharma said that the once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets, is an oral antidiabetic fixed-dose combination medication with the extended-release formulation of metformin.
Actoplus met XR combines Actos (pioglitazone HCL) and metformin in a single tablet. Actos directly targets insulin resistance, and metformin acts primarily by reducing the amount of glucose produced in the liver. These medications work in combination, along with diet and exercise, to help patients with type 2 diabetes improve glycemic control.
Takeda is the inventor and developer of ACTOS, which was launched commercially in the US in 1999.
Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Watson Laboratories, a subsidiary of Watson Pharmaceuticals, and licensed to Takeda Pharma.